EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer

63Citations
Citations of this article
42Readers
Mendeley users who have this article in their library.

Abstract

Purpose:: Activating mutations in the epidermal growth factor receptor (EGFR) are associated with enhanced response to EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC), whereas KRAS mutations translate into poor patient outcomes. We hypothesized that analysis of plasma for EGFR and KRAS mutations from shed tumor DNA would have clinical utility. Methods: An allele-specific polymerase chain reaction assay using Scorpion-amplification refractory mutation system (DxS, Ltd) was used to detect mutations in plasma DNA from patients with advanced stage NSCLC treated as second- or third-line therapy on a phase I/II trial of docetaxel plus intercalated erlotinib. Results: EGFR mutations were detected in 10 of 49 patients (20%). Six (12%) had single activating mutations in EGFR, associated with improved progression-free survival (median, 18.3 months), compared with all other patients (median, 3.9 months; p = 0.008), or those with wild-type EGFR (median, 4.0 months; p = 0.012). Four of 49 patients harbored a de novo T790M resistance mutation (median progression-free survival, 3.9 months). EGFR mutational status was associated with clinical response (45 assessable, p = 0.0001); in the six patients with activating mutations, all achieved complete (33%) or partial (67%) response. All CR patients had E19del detectable in both tumor and plasma. KRAS mutations were detected in two of 49 (4%) patients, both of whom had rapid progressive disease. Conclusions: Activating EGFR mutations detected in shed DNA in plasma are significantly associated with favorable outcomes in patients with advanced NSCLC receiving docetaxel plus intercalated erlotinib. The addition of docetaxel in this schedule did not diminish the efficacy of erlotinib against patients with EGFR activating mutations. © 2009 by the International Association for the Study of Lung Cancer.

Author supplied keywords

References Powered by Scopus

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non-Small-Cell Lung Cancer to Gefitinib

10532Citations
N/AReaders
Get full text

EGFR mutations in lung, cancer: Correlation with clinical response to gefitinib therapy

8911Citations
N/AReaders
Get full text

Cancer statistics, 2007

7681Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Cell-free DNA in the blood as a solid tumor biomarker-A critical appraisal of the literature

293Citations
N/AReaders
Get full text

Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non-Small-Cell Lung Cancer Patients with EGFR Mutations

283Citations
N/AReaders
Get full text

Highly sensitive droplet digital PCR method for detection of EGFR-activating mutations in plasma cell-free DNA from patients with advanced non-small cell lung cancer

182Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

MacK, P. C., Holland, W. S., Burich, R. A., Sangha, R., Solis, L. J., Li, Y., … Gandara, D. R. (2009). EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer. Journal of Thoracic Oncology, 4(12), 1466–1472. https://doi.org/10.1097/JTO.0b013e3181bbf239

Readers' Seniority

Tooltip

Researcher 11

46%

PhD / Post grad / Masters / Doc 10

42%

Professor / Associate Prof. 3

13%

Readers' Discipline

Tooltip

Medicine and Dentistry 21

68%

Agricultural and Biological Sciences 6

19%

Pharmacology, Toxicology and Pharmaceut... 2

6%

Biochemistry, Genetics and Molecular Bi... 2

6%

Save time finding and organizing research with Mendeley

Sign up for free